Gilead tees up $11B in new US manufacturing, R&D investments

Title

Gilead Adds $11 Billion to U.S. Manufacturing and R&D Investments Amid Policy Pressures

Gilead Sciences is investing an additional $11 billion into its U.S. manufacturing and research & development operations, responding to political pressures and competitive moves by other major pharmaceutical companies3 5.
This $11 billion boost supplements Gilead’s previously committed $21 billion, bringing its total planned U.S. investment to $32 billion over five years4.
The new outlay will fund the construction of three new facilities and upgrades to three existing sites in the U.S., with a focus on advanced technology and engineering initiatives4.
Of the $11 billion, $4 billion is allocated to capital projects like labs and equipment, and $5 billion is designated for additional areas within R&D and operations2.
The company estimates this expansion will create about 3,000 new U.S. jobs by 2028, including 800 direct positions and 2,200 indirect opportunities4.
Gilead projects that this combined investment will generate $43 billion in value for the U.S. economy4.
The move comes as several Big Pharma companies, including Bristol Myers Squibb, intensify domestic investments, particularly in anticipation of potential tariffs and shifting U.S. trade policies1 4.
In March 2024, pharma imports to the U.S. reached over $50 billion, underscoring the strategic importance of bolstering domestic production capacity4.